ANTIVIRAL EFFECT OF INOSINE PRANOBEX IN HPV-ASSOCIATED DISEASES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The department of obstetrics and gynecology of the Faculty of medicine; The division of experimental researches and modeling; The department of microbiology, virology and immunology; Moscow state university of medicine and dentistry; The family planning center of the Western administrative district of Moscow, Russia Objectives. To determine an antiviral efficiency of isopronosine in HPV-associated diseases, and adverse effects of Isoprinosine depending on different patients’ age population. Subjects and methods. Comparative analysis of results of 5650 patients with HPV-associated gynecological diseases, collected by 352 physicians from 33 cities of Russian Federation by standardized scoring system of main clinical and laboratory parameters (patient complaints, lesions and PCR DNA HPV testing) before and after isoprinosine treatment in mono and combined with routine methods depending on different patients’ age population. Results. There was a spontaneous elimination of HPV particles in 22.6% cases after 6 months follow up period in non-treated women, while HPV negative results were obtained in 35.5% cases after routine treatments, in 54.8% cases - after isoprinosine mono-treatment and in 84.2% — after Isoprinosine combined mode. There was significantly decreased degree of patient complains and remaining lesions after combined mode of isoprinosine than analogous parameters of both other treatment groups. Main adverse effects of isoprinosine were related with digestive system complains in young patients and skin (dryness and rash) in older women and complains on a pain in joints in 2 patients above 46 years. Conclusion. Regression of HPV-associated diseases with significantly decreased degree of patients complains and remaining lesions, as well as elimination of viral particles were demonstrated after treatment with combined mode of isoprinosine in comparison with both routine treatments and Isoprinosine mono-treatment options. Antiviral effects of isoprinosine can be related with activation of lymphocytes subsets, are responsible for the host antiviral defense, and synergistic action of different treatment modalities of HPV.

Full Text

Restricted Access

References

  1. Елисеева М.Ю., Мынбаев О.А. Вспомогательная иммунотерапия ВПЧ-ассоциированных поражений слизистых оболочек и кожи урогенитальной и перианальной локализации (Систематический обзор литературы и МЕТА-анализ применения Инозина пранобекса) // Гинекология. — 2010. — Т. 11, № 5. — С. 22—33.
  2. Елисеева М.Ю., Мынбаев О.А. Роль иммунотерапии в решении проблем ВПЧ-ассоциированных патологических поражений слизистых оболочек и кожи // Акуш. и гин. — 2011. № 4. — С. 104—111.
  3. Мынбаев О.А., Елисеева М.Ю. Вспомогательная иммунотерапия ВПЧ-ассоциированных поражений кожи и слизистых оболочек (обзор литературы) // Гинекология. — 2011. — Т. 13, № 3. — С. 32—41.
  4. Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р. Возможности терапии ВПЧ-ассоциированных заболеваний гениталий у женщин // Акуш. и гин. — 2011. — № 5. — С. 123—128.
  5. Cameron J.E., Mercante D., O’Brien M. et al. The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults // Sex. Transm. Dis. — 2005. — Vol. 32, № 11. — P. 703—709.
  6. Coleman N., Birley H.D., Renton A.M. et al. Immunological events in regressing genital warts // Am. J. Clin. Pathol. — 1994. — Vol. 102. — P. 768—774.
  7. Ganguly N., Waller S., Stasik C.J. et al. Giant anal condylomatosis after allogeneic bone marrow transplantation: a rare complication of human papilloma virus infection // Transpl. Infect. Dis. — 2008. — Vol. 10, № 1. — P. 56—58.
  8. Georgala S., Katoulis A.C., Befon A. et al. Oral inosiplex in the treatment of cervical condylomata acuminata: a randomized placebo-controlled trial // Br. J. Obstet. Gynaecol. — 2006. — Vol. 113, № 9. — P. 1088—1091.
  9. Gormley R.H., Kovarik C.L. Dermatologic manifestations of HPV in HIV-infected individuals // Curr. HIV/AIDS Rep. — 2009. — Vol. 6. — P. 130—138.
  10. Jenkins M., Chiriva-Internati M., Mirandola L. et al., Perspective for prophylaxis and treatment of cervical cancer: an immunological approach // Int. Rev. Immunol.—2012. — Vol. 31, № 1. — P. 3—21.
  11. Kodner C.M., Nasraty S. Management of genital warts // Am. Fam. Physician. — 2004. — Vol. 70, № 12. — P. 2335—2342.
  12. Leigh I.M., Glover M.T. Skin cancer and warts in immunosuppressed renal transplant recipients // Rec. Results Cancer Res. — 1995. — Vol. 139. — P. 69—86.
  13. Ohnishi H., Kosuzume H., Inaba H. et al. Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent // Infect. and Immun. — 1982. — Vol. 38, № 1. — P. 243—250.
  14. Palefsky J. Human papillomavirus-related disease in people with HIV // Curr. Opin. HIV AIDS. — 2009. — Vol. 4. — P. 52—56.
  15. Petry K.U., Scheffel D., Bode U. et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions // Int. J. Cancer. — 1994. — Vol. 57. — P. 836—840.
  16. Scott M., Stites D.P., Moscicki A.B. Th1 cytokine patterns in cervical human papillomavirus infection // Clin. Diagn. Lab. Immunol. — 1999. — Vol. 6. — P. 751—755.
  17. Song S.H., Lee J.K., Lee N.W et al. Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV) // Gynecol. Oncol. — 2008. — Vol. 108. — P. 543—548.
  18. Tay S.K. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study // Int. J. STD AIDS. — 1996. — Vol. 7, № 4. — P. 276—280.
  19. Wiley D.J., Douglas J., Beutner K. External genital warts: diagnosis, treatment, and prevention // Clin. Infect. Dis. — 2002. — Vol. 35 (suppl. 2). — P. 210—224.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media